Livelong Media has unveiled the complete roster of speakers and sponsors for the Livelong Women's Health Summit, taking place on September 25–26, 2026, at the Hilton Midtown in New York City. Following the overwhelming success of its sold-out debut in San Francisco, this year's event is expected to welcome more than 2,000 attendees and over 100 leading experts for two days of evidence-based discussions on women's health, including aging, hormones, brain health, and the science behind today's rapidly expanding wellness and treatment landscape.

Academy Award-winning actress and activist Jane Fonda will headline the opening session, "The Third Act: Aging Successfully." Joining her are renowned beauty entrepreneur Bobbi Brown, menopause specialist Dr. Mary Claire Haver, exercise physiologist Dr. Stacy Sims, orthopedic surgeon and Unbreakable author Dr. Vonda Wright, Dr. Jessica Shepherd, Chief Medical Officer of Hers, fertility expert Dr. Natalie Crawford, and psychiatrist Dr. Sasha Hamdani, alongside a diverse lineup of clinicians, scientists, researchers, and health innovators.

"Women are looking for facts—not marketing. They want access to research, honest discussions about benefits and risks, and the freedom to make informed decisions about their health," said Katie Gaudu, Chief Operating Officer of Livelong Media. "Our summit is designed to provide exactly that: a trusted space for meaningful conversations without pushing products or miracle solutions."

The two-day agenda features keynote presentations, 15 specialized masterclasses centered on longevity, and 40 interactive roundtable sessions exploring topics such as hormonal changes, ovarian aging, the effects of declining estrogen, inflammation and cognitive health, AI-powered personalized medicine, and navigating midlife in the workplace.

The summit is made possible through the support of a broad network of sponsors whose contributions help fund educational programming, research presentations, discounted and complimentary student tickets, and an interactive exhibition showcasing innovations in women's healthcare. Rather than viewing them simply as sponsors, Livelong Media recognizes these organizations as mission-driven partners committed to advancing women's health education.

The 2026 partner lineup includes AAUW, Align Tech, Ammortal, Arid Blayne, Athletech News, Buck Institute, Carolyn Rowan Center at Mt. Sinai, City Pickle, Cntrl+, EightSleep, Elixir Play, Evermore Pet Food, Experience Life, Function Health, Gina, Gloria, Gotham, Hailey Happens Fitness, Health & Fitness Association, Human Longevity Inc., Jona Health, Kathy Kamei, KeraFactor by Skin QRI, Lume Health, Lumisque, Mblue Labs, Menrva, Monarch, Parasym, Portfolia, Pvolve, ReVelist, Seli Strength, Siemens, Spears Physical Therapy, Sybil Wellness, The 'Pause Life, Throne Science, Timeline, Twelve 28, Vital Ventures, Women's Health Forum NYC, and Zero Gravity.

"Each of these organizations has invested in something far greater than brand visibility," Gaudu added. "Their support allows us to deliver credible, research-driven education instead of sales-driven messaging. This summit exists because they believed in creating a platform where women can access reliable information and make empowered health decisions."

In return, sponsors gain exposure to a highly engaged national audience seeking trustworthy health information rather than conventional advertising. Throughout the event, participating organizations will be integrated into the educational experience through the exhibition hall and program activities, sharing space alongside respected physicians and researchers. Livelong Media says this editorial-first approach reflects the trust it has built with its audience of more than 300,000 monthly readers.

The New York summit also marks the beginning of a broader expansion, with additional Women's Health Summit events scheduled for Dallas, San Francisco, and Boston in 2027, before returning to New York.

Healthcare professionals attending the conference can earn up to 10 CE/CME credits across 10 credentialing organizations, including AMA PRA Category 1, ACPE, and ANCC. An optional two-hour clinical workshop on Saturday afternoon, produced in partnership with Pinnacle Conference, is expected to offer an additional 2.0 AMA PRA Category 1 Credits™ (pending accreditation) for physicians, nurse practitioners, physician assistants, and allied health professionals.

Conference registration is priced at $595 for General Admission, $695 for Premier access, and $1,095 for the VIP experience. VIP attendees will receive exclusive access to a Friday evening reception with featured speakers and a private meet-and-greet with Jane Fonda. Discounted group pricing is also available for organizations and teams.

Additional event information, the complete agenda, and ticket registration are available through the official Livelong Women's Health Summit website.

Newronika S.p.A., a Milan-headquartered medical technology company specializing in advanced deep brain stimulation (DBS), has secured CE Mark certification for the newest commercial version of its αDBS adaptive DBS system. The updated platform now features complete integration with WebBioBank, the company's proprietary cloud-based platform for neural data management.

The certification represents a significant regulatory achievement, making αDBS the first adaptive DBS system approved to continuously monitor neural activity, automatically tailor stimulation based on each patient's therapy settings, and securely transmit this information to a fully integrated cloud-based neural data platform.

Developed through more than two decades of research and innovation, Newronika's technology is designed to interpret the brain's electrical signals and optimize therapy delivery. The system aims to improve treatment effectiveness while minimizing side effects, reducing the frequency of clinical appointments, and easing the overall care burden for both patients and healthcare professionals.

"This certification validates our vision of a fully connected, data-driven approach to neuromodulation therapy, and opens a new era in personalized treatment for patients living with Parkinson's disease and other neurological conditions," said Lorenzo Rossi, PhD, Co-Founder, CEO and CTO of Newronika.

Unlike conventional DBS systems that provide constant stimulation regardless of changes in a patient's neurological state, αDBS® dynamically adapts therapy in real time. Using its patented Adaptive Therapy Stim Engine, the system continuously monitors local field potentials (LFPs), interprets neural activity, and automatically fine-tunes stimulation to help patients remain within their ideal therapeutic range.

The αDBS platform combines an implantable pulse generator (IPG), a physician programming interface, and a patient remote control that supports convenient at-home data collection. Together, these components create a connected care ecosystem in which patient information is transmitted continuously, providing clinicians with long-term data that can help refine treatment strategies over time.

WebBioBank Powers Personalized Neuromodulation
A key feature of the newly certified release is the complete integration of WebBioBank, Newronika's dedicated neural data platform, with the αDBS® implant. The cloud-based system gathers and analyzes neuronal activity alongside clinical information from participating healthcare centers, creating a growing repository of anonymized longitudinal data that expands with each new patient.

Initially developed with funding from the Italian Ministry of Education and validated through peer-reviewed scientific research, WebBioBank has contributed to a deeper understanding of the neurophysiology of deep brain structures, the mechanisms underlying DBS therapy, and the development of next-generation adaptive stimulation algorithms. By providing a common analytical platform for clinicians, researchers, and Newronika, the system supports ongoing advances in personalized neuromodulation treatments.

The platform incorporates a robust de-identification framework designed to safeguard patient privacy while enabling secure data sharing across participating medical centers.

Can advanced mathematical models help detect heart disease before symptoms even appear? Increasingly, the answer is yes. By analyzing data collected during routine medical visits, these models can uncover early warning signs that might otherwise go unnoticed.

“We now have advanced AI tools that allow us to gather and analyze enormous volumes of medical data in ways that weren’t possible before,” explained Nina Goodheart, Senior Vice President and President of the Structural Heart and Aortic division at Medtronic. “Artificial intelligence helps us detect specific heart conditions earlier and enables faster, personalized treatment.”

Take aortic stenosis (AS) as an example—a serious heart valve condition affecting roughly 250,000 Americans each year. In AS, the aortic valve narrows, reducing blood flow from the heart to the body. The symptoms often develop gradually and vary between individuals, making it difficult to diagnose early.

However, every time you visit a doctor, a trail of health data is recorded in your Electronic Health Record (EHR). This data may include lifestyle factors, test results, physician notes, and more. Hidden within that information could be signs of a developing heart issue like AS—but finding them manually is like searching for a needle in a haystack.

That’s where artificial intelligence becomes vital.

“AI helps bring structure to overwhelming and complex health data,” said Chris Rogers, Senior Director of Strategic Provider Solutions at Tempus AI, a Chicago-based company that uses data science to enhance medical diagnostics. “Our algorithms are designed to detect subtle patterns that may not be visible to clinicians reviewing patient records individually.”

Tempus Next, the company’s AI-powered software, uses around 60 advanced algorithms to identify gaps in care for 15 different cardiovascular diseases, including AS. “Medical data is incredibly nuanced,” Rogers noted. “Our technology is built to adapt to the unique context of each healthcare provider, offering insights that are both specific and actionable.”

The software scans your EHR—including physician notes—and matches your health data to established diagnostic criteria for AS. If your data meets enough indicators, the system alerts your healthcare provider, potentially prompting further evaluation or treatment.

This isn’t just a concept—it’s already delivering results.

In a recent collaboration with the John Brancaccio St. Francis Hospital and Heart Center in New York, Tempus Next identified 388 patients who met criteria for AS or another serious heart condition but weren’t yet receiving appropriate treatment. These findings were flagged for doctors, offering a chance for earlier intervention.

Now, Medtronic and Tempus are expanding their work through a new clinical trial called ALERT, which will review patient records from six additional healthcare sites. The study aims to identify not only patients who are being overlooked but also the systemic reasons behind delayed diagnoses—ultimately helping to design better care processes.

“The underdiagnosis of severe aortic stenosis is a widespread issue that can be deadly within two years if untreated,” said Dr. Wayne Batchelor, Interventional Cardiologist and Chair of the ALERT study’s steering committee. “Our goal is to create more timely, equitable treatment pathways and break down the barriers preventing proper care.”

The potential impact of this technology is enormous.

“It’s inspiring to think about what’s possible,” Goodheart said. “We could one day apply this to millions of patients, catching AS before it becomes critical and improving or extending countless lives. The numbers speak for themselves.”

And that’s one kind of math that could truly save lives.